Cost-Effectiveness Analysis of Intrathecal Baclofen Therapy in Japan

被引：7

作者：

Hattori, Naoyuki ^{[1
]}

Hirayama, Teruyasu ^{[1
]}

Katayama, Yoichi ^{[1
]}

机构：

[1] Nihon Univ, Dept Neurol Surg, Sch Med, Itabashi Ku, Tokyo 1738610, Japan

来源：

NEUROLOGIA MEDICO-CHIRURGICA | 2012年 / 52卷 / 07期

关键词：

intrathecal baclofen therapy; quality of life; cost-utility analysis; SPASTICITY; MANAGEMENT; INFUSION;

D O I：

10.2176/nmc.52.482

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Intrathecal baclofen (ITB) therapy was approved for health insurance coverage in 2005 for the treatment of patients whose spasticity could not be adequately controlled by conventional therapy, and is currently being used to treat around 300 patients nationwide in Japan. Various reports have examined the efficacy and safety of ITB therapy, but no report has evaluated the patient quality of life and medical costs in Japan. A cost-utility analysis of ITB was conducted by time period in six severely spastic patients admitted to our university hospital between 2005 and 2010 for ITB therapy. The average cost of ITB therapy per quality-adjusted life year (QALY; number of years survival in perfect health) 5 years after surgery was 1,554,428 yen, below the 6 million yen willingness-to-pay threshold for 1 QALY. This study shows that ITB therapy in Japan is an outstanding treatment in medicoeconomic terms.

引用

页码：482 / 487

页数：6

共 23 条

[1] Cost-effectiveness Modeling of Intrathecal Baclofen Therapy Versus Other Interventions for Disabling Spasticity
Bensmail, D.
Ward, A. B.
Wissel, J.
Motta, F.
Saltuari, Leopold
Lissens, J.
Cros, S.
Beresniak, A.
[J]. NEUROREHABILITATION AND NEURAL REPAIR, 2009, 23 (06) : 546 - 552
[2] Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy
de Lissovoy, Gregory
Matza, Louis S.
Green, Hannah
Werner, Meghan
Edgar, Terence
[J]. JOURNAL OF CHILD NEUROLOGY, 2007, 22 (01) : 49 - 59
[3] Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis
Devlin, N
Parkin, D
[J]. HEALTH ECONOMICS, 2004, 13 (05) : 437 - 452
[4] Engrand N, 2000, Med Trop (Mars), V60, P385
[5] COST AND HEALTH IMPLICATIONS OF CHOLESTEROL LOWERING
GOLDMAN, L
GORDON, DJ
RIFKIND, BM
HULLEY, SB
DETSKY, AS
GOODMAN, DS
KINOSIAN, B
WEINSTEIN, MC
[J]. CIRCULATION, 1992, 85 (05) : 1960 - 1968
[6] Intrathecal baclofen therapy in children with intractable spastic cerebral palsy: a cost-effectiveness analysis
Hoving, M. A.
Evers, S. M. A. A.
Ament, A. J. H. A.
van Raak, E. P. M.
Vles, J. S. H.
[J]. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2008, 50 (06) : 450 - 455
[7] Ikegami N, 2001, HDB ESTIMATION QOL, P45
[8] Japan National Council of Social Welfare Department of Welfare for Elderly Persons, 1995, REP SURV PROGR SERV, P131
[9] Willingness to pay for a quality-adjusted life year: Implications for societal health care resource allocation
King, JT
Tsevat, J
Lave, JR
Roberts, MS
[J]. MEDICAL DECISION MAKING, 2005, 25 (06) : 667 - 677
[10] Ministry of Justice, 2010, BRIEF REP SAMD AKK M, P2

← 1 2 3 →